联环药业(600513) - 2021 Q3 - 季度财报
JLPCJLPC(SH:600513)2021-10-27 16:00

Financial Performance - The company's revenue for Q3 2021 was CNY 410,834,846.19, representing a year-on-year increase of 17.80%[5] - The net profit attributable to shareholders for the same period was CNY 31,575,269.77, showing a decrease of 8.13% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 30,884,326.77, with a slight increase of 0.11% year-on-year[5] - Total revenue for the first three quarters of 2021 reached ¥1,169,942,600.71, an increase of 21.3% compared to ¥964,639,367.67 in the same period of 2020[18] - Net profit for the first three quarters of 2021 was ¥100,536,929.89, representing a growth of 7.1% from ¥93,211,779.26 in the same period of 2020[20] - Earnings per share for the first three quarters of 2021 was ¥0.30, compared to ¥0.28 in the same period of 2020[20] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 2,206,398,857.06, reflecting a growth of 7.68% from the end of the previous year[6] - The total assets as of the end of Q3 2021 amounted to ¥2,206,398,857.06, an increase from ¥2,049,066,254.48 at the end of Q3 2020[16] - Total liabilities as of the end of Q3 2021 were ¥955,619,190.43, compared to ¥867,053,818.55 in the same period of 2020[16] - The total liabilities as of Q3 2021 were ¥823,011,318.55, showing a marginal decrease from ¥823,407,300.30 at the beginning of the year[27] - Total liabilities amounted to approximately $867.05 million, with a slight increase of $2.38 million compared to the previous period[28] - The company's total assets were approximately $2.05 billion, with a total increase of $2.37 million from the previous period[28] Shareholder Equity - The equity attributable to shareholders increased by 5.26% to CNY 1,127,890,131.15 compared to the end of the previous year[6] - The company's equity attributable to shareholders reached ¥1,127,890,131.15, up from ¥1,071,555,563.57 in the previous year[16] - Total equity reached approximately $1.18 billion, reflecting a minor decrease of $8,700.52 compared to the previous period[28] - The company's retained earnings stood at approximately $461.43 million, showing a negligible decrease of $4,437.27[28] - The company's total equity attributable to shareholders was approximately $1.07 billion, with a minor decrease of $4,437.27[28] Cash Flow - The operating cash flow for the year-to-date period decreased by 37.35% to CNY 66,054,135.50, attributed to increased prepayments and employee compensation[9] - Operating cash inflow for the first three quarters of 2021 reached ¥1,394,547,714.80, a 22% increase from ¥1,144,458,703.81 in the same period of 2020[24] - Net cash flow from operating activities for Q3 2021 was ¥66,054,135.50, down 37% from ¥105,436,490.43 in Q3 2020[24] - Cash outflow from investment activities in Q3 2021 was ¥192,590,008.16, compared to ¥166,607,750.28 in Q3 2020, indicating increased investment spending[24] - Net cash flow from financing activities for Q3 2021 was ¥123,265,225.16, significantly up from ¥38,247,912.19 in Q3 2020, reflecting improved financing conditions[24] - The total cash and cash equivalents at the end of Q3 2021 stood at ¥225,988,816.78, down from ¥277,838,765.28 at the end of Q3 2020[25] Research and Development - Research and development expenses for the first three quarters of 2021 were ¥39,119,611.11, an increase from ¥31,461,108.16 in the same period of 2020[19] Government Subsidies - The company received government subsidies amounting to CNY 834,904.44 during the quarter, contributing to its financial performance[8] Other Financial Metrics - The basic earnings per share for Q3 2021 was CNY 0.11, down 8.33% from the same period last year[5] - The weighted average return on equity for Q3 2021 was 2.84%, a decrease of 0.50 percentage points year-on-year[6] - The company reported a total of ¥42,750.00 in fair value gains in Q3 2021, compared to a loss of ¥10,260.00 in Q3 2020[19] - Cash inflow from other operating activities in Q3 2021 was ¥59,956,067.21, an increase of 61% compared to ¥37,180,612.77 in Q3 2020[24] - Cash flow from the disposal of fixed assets in Q3 2021 was ¥8,000,000.00, a decrease from ¥34,151,444.84 in Q3 2020, indicating reduced asset disposals[24] Accounting Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement adjustments[28]

JLPC-联环药业(600513) - 2021 Q3 - 季度财报 - Reportify